pemigatinib
incyte,specialised therapeutics
#fight202 #wcgic2022
pemigatinib confirmed durable response and os benefit fgfr2, molecular testing is needed! 
MD, PhD. GI Medical Oncologist @istitutotumori. @myESMO #YOC & #SoMe committee member. European. Beauty seeker. #endowarrior. Tweets are my own.